BRNS:NSD-Barinthus Biotherapeutics plc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.7299

Change

+0.02 (+3.53)%

Market Cap

USD 0.04B

Volume

2.30K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-17 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 126.52B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 69.68B
ARGX argenx NV ADR

N/A

USD 35.43B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 30.51B
ONC BeiGene, Ltd.

N/A

USD 26.35B
RPRX Royalty Pharma Plc

N/A

USD 19.31B
SMMT Summit Therapeutics PLC

N/A

USD 14.57B
INSM Insmed Inc

N/A

USD 12.52B
INCY Incyte Corporation

N/A

USD 11.72B
BMRN Biomarin Pharmaceutical Inc

N/A

USD 11.50B

ETFs Containing BRNS

BEDZ AdvisorShares Hotel ETF 6.50 % 0.00 %

N/A

USD 3.20M
DVP Roundhill Acquirers Deep .. 1.23 % 0.48 %

N/A

N/A
DEEP Roundhill Acquirers Deep .. 1.23 % 0.00 %

N/A

USD 0.02B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -39.58% 36% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -39.58% 36% F 20% F
Trailing 12 Months  
Capital Gain -73.07% 26% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -73.07% 26% F 11% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -19.61% 26% F 14% F
Dividend Return -19.61% 26% F 14% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 30.01% 87% B+ 61% D-
Risk Adjusted Return -65.35% 18% F 11% F
Market Capitalization 0.04B 34% F 28% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector